Fablyn lasofoxifene regulatory update

FDA's Reproductive Health Drugs Advisory Committee voted 9-3 with 1 abstention on Monday that Fablyn lasofoxifene from Pfizer had a favorable benefit/risk profile to treat osteoporosis in postmenopaus...